Aurinia Pharmaceuticals Inc


Aurinia Pharmaceuticals Inc (AUPH): Voclosporin’s Long-Term Phase 2 Data Points for Assessing the Probability of Phase 3 Success

This is an exciting time for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) and its shareholders. The shares have gone up over 120% after the drug maker announced positive …

Moving on Up: Ocera Therapeutics Inc (OCRX), Aurinia Pharmaceuticals Inc (AUPH)

Ocera Therapeutics Inc (NASDAQ:OCRX) and Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) are soaring up, up, and away into the biotech-verse stratosphere today, and Aegis and …

Aurinia Pharmaceuticals Inc (AUPH) Announces 4Q and Full Year 2016 Financial Results

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has released its financial results for the fourth quarter and year ended December 31, 2016. Amounts, unless specified otherwise, …

Company Update (NASDAQ:AUPH): Aurinia Pharmaceuticals Inc Announces Acceptance of Voclosporin Late-Breaking Presentation at the NKF 2017 Spring Clinical Meetings

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced that its late-breaking abstract for voclosporin has been accepted for oral presentation at the National Kidney Foundation (NKF) …

Aurinia Pharmaceuticals Inc (AUPH) Shares Continue to Soar as Voclosporin Success Opens Partnership Possibilities

  Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares have been skyrocketing following the biotech firm’s major success with its Phase IIb trial evaluating voclosporin (VCS) …

H.C. Wainwright Raises Price Target on Aurinia Pharmaceuticals Inc (AUPH) As Voclosporin Just Keeps Getting Better

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are currently rising almost 8% after the biotech firm released the rare, good news that its drug in …

Canaccord Applauds Aurinia Pharmaceuticals Inc (AUPH) As Shares Shatter Through the Roof at 66%

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is on fire today with shares zooming up 66% in pre-market trading after the biotech firm’s drug voclosporin scored …

Thursday’s Biotech Insights: Aurinia Pharmaceuticals Inc (AUPH), Puma Biotechnology Inc (PBYI)

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares skyrocketed over 65% this morning, after the drug maker announced top-line results from its AURA-LV Phase IIb study …

Aurinia Pharmaceuticals Inc (AUPH) Announces Top-Line Results From Phase IIb AURA-LV Study in Lupus Nephritis

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced top-line results from its Phase IIb AURA-LV (AURA) study in lupus nephritis (LN). At 48 weeks, the trial …

FBR Envisions Bullish Forecast for Aurinia Pharmaceuticals Inc (AUPH) Under New CEO

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced on Monday that Richard Glickman would be taking on new roles as chairman and CEO of the firm …